Atrial natriuretic peptide augments the variability of sympathetic nerve activity in human heart failure

Journal of Hypertension
T KuboJ S Floras

Abstract

Activation of the sympathetic nervous system, decreased heart rate variability (HRV), and loss of modulation of muscle sympathetic nerve activity (MSNA) within the low frequency (LF, 0.05-0.15 Hz) range are three adverse features of advanced congestive heart failure (CHF). In healthy men, atrial natriuretic peptide (ANP) infusion attenuates reflex increases in MSNA and reduces LF components of HRV spectral power. Sympathoinhibitory actions have also been documented in CHF, but effects on the variability of MSNA and HRV have not been described. Heart rate and MSNA were recorded in 10 men (aged 39 +/- 3 years, mean +/- SE) with dilated cardiomyopathy (mean EF 20 +/- 4%) treated with angiotensin converting enzyme (ACE) inhibitors. Subjects received i.v. ANP (50 microg bolus then 50 ng/kg/min) and nitroglycerin (NTG, 8 mg/min) as a hemodynamic control. Signals at baseline, and 13-20 min into each infusion were submitted to spectral analysis. ANP had no effect on HRV, but increased MSNA LF (from 7.9 +/- 1.5 to 12.1 +/- 2.6 U2; P< 0.02) and total spectral power (from 47.9 +/- 5.4 to 61.9 +/- 6.8 U2; P < 0.05). NTG had no effect on the variability of MSNA or HRV. In CHF patients receiving ACE inhibitors, ANP (i) does not suppress HRV ...Continue Reading

References

Aug 15, 1992·The American Journal of Cardiology·D ElsnerG A Riegger
Sep 1, 1991·Journal of Applied Physiology·Y Yamamoto, R L Hughson
Sep 27, 1984·The New England Journal of Medicine·J N CohnT Rector
Nov 1, 1995·Journal of the American College of Cardiology·D M KayeM D Esler
Oct 1, 1994·The American Journal of Physiology·T M ButlerM J Siegman
Jul 1, 1997·The American Journal of Physiology·O CulicJ Schrader
Mar 30, 1999·Circulation·P van de BorneV K Somers
Jan 12, 2000·Journal of Cardiovascular Pharmacology·E R AzevedoJ D Parker
Jan 14, 2000·Journal of Cardiac Failure·C J Barrett, H D Schultz

❮ Previous
Next ❯

Citations

Apr 27, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Toshihiko KuboJohn S Floras
Apr 30, 2015·Journal of Hypertension·Jens Jordan, Guido Grassi
Jul 23, 2002·Journal of Applied Physiology·François PiquardBernard Geny
Jun 30, 2021·Autonomic Neuroscience : Basic & Clinical·Kanokwan BunsawatD Walter Wray

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.